Epigenomics AG Reports H1 2025 Loss of 204 TEUR, Sales Increase to 4 TEUR from 0 TEUR

Epigenomics AG has released its preliminary results for the first half of 2025, reporting a reduced net loss of 204 thousand EUR, a significant improvement from the loss of 796 thousand EUR in the same period last year. The company recorded revenues of 4 thousand EUR, an increase from 0 EUR in the first half of 2024. Total available liquid funds stood at 764 thousand EUR as of June 30, 2025, down from 927 thousand EUR at the end of 2024. The financial result improved to +22 thousand EUR from -164 thousand EUR in the previous year, attributed entirely to interest income, contrasting with last year’s financial result impacted by write-downs on financial assets amounting to 178 thousand EUR. Other operational expenses included non-deductible input tax of 45 thousand EUR from the previous year, accounting and audit costs of 25 thousand EUR, expenses related to stock market listing and capital market communication of 23 thousand EUR, exchange rate-related expenses of 19 thousand EUR, legal and consulting costs of 19 thousand EUR, and losses on receivables of 18 thousand EUR. The preliminary balance sheet as of June 30, 2025, showed negative equity of 11.065 million EUR, slightly up from negative equity of 10.861 million EUR at the end of 2024. The management has maintained its annual forecast for 2025, projecting a net loss between 0.1 million EUR and 0.5 million EUR. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Epigenomics AG published the original content used to generate this news brief via pressetext (Ref. ID: 20250710026) on July 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)